Caribou Biosciences, Inc. (CRBU)

Market Cap	144.51M
Revenue (ttm)	33.40M
Net Income (ttm)	-115.26M
Shares Out	90.32M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,662,915
Open	1.600
Previous Close	1.590
Day's Range	1.535 - 1.640
52-Week Range	1.535 - 8.590
Beta	2.43
Analysts	Strong Buy
Price Target	15.67 (+879.38%)
Earnings Date	Aug 6, 2024

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBU

Financial Performance

In 2023, CRBU's revenue was $34.48 million, an increase of 148.91% compared to the previous year's $13.85 million. Losses were -$102.07 million, 2.66% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $15.67, which is an increase of 879.38% from the latest price.

Price Target

$15.67

(879.38% upside)

Analyst Consensus: Strong Buy